These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 30610356

  • 1. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
    Huang YS, Chen JL, Chen JY, Lee YF, Huang JY, Kuo SH, Yen RF, Chang YC.
    Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
    [Abstract] [Full Text] [Related]

  • 2. Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer.
    Huang YS, Chen JL, Chen HM, Yeh LH, Shih JY, Yen RF, Chang YC.
    BMC Cancer; 2021 Apr 01; 21(1):348. PubMed ID: 33794813
    [Abstract] [Full Text] [Related]

  • 3. Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients.
    Huang YS, Chen JL, Hsu FM, Huang JY, Ko WC, Chen YC, Jaw FS, Yen RF, Chang YC.
    J Magn Reson Imaging; 2018 Jan 01; 47(1):191-199. PubMed ID: 28480541
    [Abstract] [Full Text] [Related]

  • 4. Correlation of Ktrans derived from dynamic contrast-enhanced MRI with treatment response and survival in locally advanced NSCLC patients undergoing induction immunochemotherapy and concurrent chemoradiotherapy.
    Wang D, Liu S, Fu J, Zhang P, Zheng S, Qiu B, Liu H, Ye Y, Guo J, Zhou Y, Jiang H, Yin S, He H, Xie C, Liu H.
    J Immunother Cancer; 2024 Jun 23; 12(6):. PubMed ID: 38910009
    [Abstract] [Full Text] [Related]

  • 5. Significance of 18F-FDG PET Parameters According to Histologic Subtype in the Treatment Outcome of Stage III Non-small-cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
    Kim E, Wu HG, Keam B, Kim TM, Kim DW, Paeng JC, Kim HJ, Chang JH.
    Clin Lung Cancer; 2019 Jan 23; 20(1):e9-e23. PubMed ID: 30266585
    [Abstract] [Full Text] [Related]

  • 6. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
    Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y, Sugimura K.
    AJR Am J Roentgenol; 2012 Jan 23; 198(1):75-82. PubMed ID: 22194481
    [Abstract] [Full Text] [Related]

  • 7. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, Marsden P, Ahmad S, Landau D.
    J Nucl Med; 2013 Jan 23; 54(1):19-26. PubMed ID: 23204495
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan 23; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 9. [Preliminary study of semi-quantitative and quantitative dynamic contrast-enhanced MRI in evaluating the response to concurrent chemoradiotherapy in patients with non-small cell lung cancer].
    Xiuli T, Han O, Ning W, Li L, Feng Y, Ying S, Peihua W, Lü L.
    Zhonghua Zhong Liu Za Zhi; 2015 Apr 23; 37(4):272-7. PubMed ID: 26462891
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
    Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, Oyen WJ, Schuurbiers OC, Bussink J.
    J Nucl Med; 2013 Sep 23; 54(9):1528-34. PubMed ID: 23864719
    [Abstract] [Full Text] [Related]

  • 11. Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy.
    Hwang SH, Yoo MR, Park CH, Jeon TJ, Kim SJ, Kim TH.
    Eur Radiol; 2013 Jun 23; 23(6):1573-81. PubMed ID: 23300040
    [Abstract] [Full Text] [Related]

  • 12. DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC.
    Tao X, Wang L, Hui Z, Liu L, Ye F, Song Y, Tang Y, Men Y, Lambrou T, Su Z, Xu X, Ouyang H, Wu N.
    Sci Rep; 2016 Oct 20; 6():35569. PubMed ID: 27762331
    [Abstract] [Full Text] [Related]

  • 13. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT.
    Ann Surg; 2013 Feb 20; 257(2):364-70. PubMed ID: 22968069
    [Abstract] [Full Text] [Related]

  • 14. Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy.
    Vojtíšek R, Baxa J, Kovářová P, Almortaza A, Hošek P, Sukovská E, Tupý R, Ferda J, Fínek J.
    Strahlenther Onkol; 2021 Jun 20; 197(6):494-504. PubMed ID: 33492444
    [Abstract] [Full Text] [Related]

  • 15. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
    Melloni G, Gajate AM, Sestini S, Gallivanone F, Bandiera A, Landoni C, Muriana P, Gianolli L, Zannini P.
    Eur J Surg Oncol; 2013 Nov 20; 39(11):1254-61. PubMed ID: 23948705
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
    Ercelep O, Alan O, Sahin D, Telli TA, Salva H, Tuylu TB, Babacan NA, Kaya S, Dane F, Ones T, Alkis H, Adli M, Yumuk F.
    Clin Transl Oncol; 2019 Apr 20; 21(4):499-504. PubMed ID: 30229391
    [Abstract] [Full Text] [Related]

  • 18. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
    Ohno Y, Yui M, Yamamoto K, Takenaka D, Koyama H, Nagata H, Ueda T, Ikeda H, Ozawa Y, Toyama H, Yoshikawa T.
    J Magn Reson Imaging; 2023 Jul 20; 58(1):174-186. PubMed ID: 36971493
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.